Manuscripts submitted for publication in Bentham Science journals are subjected to single blind peer-review, except for a selected number of patent journals where double blind review is followed. Single blind reviewing maintains the identity of the reviewers, not disclosing their names to the authors. The anonymity of reviewers ensures objective and unbiased assessment of the manuscript by reviewers.
Reviewers are advised to consider the following important aspects of a manuscript when conducting the review.
1. Reporting of Original Results:
The results reported in the manuscript must be original and authentic work of the authors. They should be devoid of any plagiarism and the material should not have been published earlier. Studies which report some reproduced results, for example a new clinical trial, may also be considered for publication.
2. Experiments and Analyses:
Experiments and other analyses should meet the recognized technical standards and must be described systematically. The research presented in a manuscript should facilitate in reaching accurate conclusions from the statistics. Methods and experiments as well as reagents should be documented in detail.
3. Interpretation of Results:
Authors should present and interpret the results and conclusions in an appropriate and comprehensive manner, clearly explaining the results and outcomes of their study. Incomplete interpretation of results may result in rejection of the manuscript.
4. Language of Composition:
The manuscript should be written in English in a clear, direct and active style, free from grammatical errors and other linguistic inconsistencies. All pages should be numbered sequentially, facilitating the reviewing and editing of the manuscript. Authors should seek professional assistance for correction of grammatical, scientific and typographical errors before submission of the revised version of the article for publication. Professional editing services may also be sought by the team available at Bentham Science at an extra charge.
5. Experiments involving Humans and Animals:
The research must meet the highest applicable international standards of the ethics of experimentation and research integrity. A brief description on ethical guidelines is given in the ‘Instructions for Authors’ of every journal published by Bentham Science.
6. Reporting guidelines (e.g. CONSORT, MIAME, STROBE, EQUATOR) and Community Standards for Data:
The manuscript should adhere to suitable reporting guidelines (e.g. CONSORT, MIAME, STROBE, EQUATOR) and community standards for data availability. Bentham Science seeks to disseminate research and therefore stipulates that the public deposition of data is as per the followed standards (for example gene sequences, microarray expression data, and structural studies). Other similar standards that may be applicable should also be followed.
IMPORTANT POINTS TO CONSIDER:
Reviewers are expected to provide advice on the following points in their review reports:
Is the manuscript written comprehensively enough to be understandable? If not, how could it be improved?
Have adequate proofs been provided for the declarations?
Have the authors addressed the previous findings fairly?
Does the paper offer enough details of its methodology to reproduce the experiments?
Bentham Science encourages authors to publish detailed protocols as supporting information online. Do any particular methods used in the manuscript warrant such a protocol?
The peer-review of a manuscript is a confidential process. Reviewers should keep the whole process completely confidential. They should consult the EiC/Senior Editor and obtain permission before consulting another colleague for help in the peer-review of the submitted manuscript.
Reviewers should not disclose any information whatsoever to anyone before publication of the manuscript.
REVIEWING PROCESS FLOW CHART:
Vladimir P. Torchilin (44972 citations) Department of Pharmaceutical Science Center for Pharmaceutical Biotechnology and Nanomedicine Northeastern University Boston, MA 02115 USA
Vladimir P. Torchilin, Ph.D., D.Sc. is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 44,000 citations of his papers with H-index of 96. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010.